Integra LifeSciences still earns less from operations than it pays in interest

Integra LifeSciences, a US medical technology company, earned an operating profit of USD 18.9m on revenue of USD 411m in Q3 2026, in US dollars. Operating profit rose 60.7% from Q3 2025, while revenue grew only 2.3%. Interest expense in the quarter was USD 23.0m, so operating profit covered it just 0.82×. Put plainly, the business earned less from its operations than it paid to its lenders in the same quarter.

Interest cover drops below one when debt grows faster than earnings, when floating rates reset higher, or when operating profit falls while borrowing stays. Here profit improved, so the weight sits on the debt side. Net profit of USD 14.9m was positive, against a loss of USD 5.4m a year earlier, so income or tax below the operating line filled the gap. The quarter's figures do not say which. Cash of USD 252m can cover a shortfall for a while, but a shortfall is still what it is.